Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Central nervous system (CNS) depression is a physiological state in which the activity of the brain and spinal cord—the core components of the CNS—is significantly slowed. This can result in decreased heart rate, reduced breathing rate, impaired consciousness, and in severe cases, coma or death. It is often caused by misuse or overdose of CNS depressant drugs, which enhance the effect of GABA, an inhibitory neurotransmitter. Medical conditions and recreational drug use can also contribute. Excessive CNS depression can be fatal.
Enhancement of GABAergic neurotransmission, reduction of neuronal excitability.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central Nervous System Depression (None).